Physician profile
Arunkumar Sanjeevi
NPI 1932181070
$1,185.51
in general payments reported to CMS, 2019-2025
17 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.99 · 2020: $121 · 2021: $80.90 · 2022: $125 · 2023: $392 · 2024: $249 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $470.91 |
| Education | $299.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $361.54 | 2022-2025 | Jakafi, Niktimvo |
| Celgene Corporation | $186.91 | 2022-2025 | Reblozyl, Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $117.03 | 2019-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $92.45 | 2021-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Astrazeneca Pharmaceuticals Lp | $55.14 | 2019-2022 | |
| Acceleron Pharma, INC. | $50.69 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $49.63 | 2020-2024 | Opdivo |
| Glaxosmithkline, LLC. | $41.04 | 2024 | Zejula, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $38.14 | 2020 | |
| Genentech USA, INC. | $35.80 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $31.91 | 2022 | |
| Myriad Genetic Laboratories, INC. | $27.23 | 2024 | Precisetumor |
| Eisai INC. | $25.33 | 2020 | |
| Lilly USA, LLC | $20.35 | 2019 | |
| Blueprint Medicines Corporation | $19.39 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.68 | 2023 | |
| Tempus Ai, INC | $14.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arunkumar Sanjeevi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.